Download Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Dengue Vaccine Market: By Vaccine Type, By End-user ) and Region Forecast 2020-2031
Dengue Vaccine Market: By Vaccine Type, By End-user ) and Region Forecast 2020-2031
Dengue vaccine market size was valued at US$ 661.9 million in 2024 and is expected to reach US$ 1,445.0 million by 2031, growing at a significant CAGR of 11.8% from 2025-2031. The market describes the area of the pharmaceutical industry devoted to the creation, manufacturing, and distribution of vaccinations intended to fend against dengue fever, a virus spread by mosquitoes. Numerous parties are involved in this market, including consumers, healthcare professionals, regulatory agencies, and makers of vaccines. As per the World Health Organization, the frequency of dengue has become significant over ongoing many years. A larger part of the cases are asymptomatic, gentle, or independent, and thus the genuine number of diseases are exceptionally under-announced. One displaying gauge demonstrates 390 million dengue diseases each year (95% valid span 284-528 million), of which 96 million show clinically.
Study Period
2025-2031Base Year
2024CAGR
12.8%Largest Market
Asia-PacificFastest Growing Market
North-America
Dengue fever or breakbone fever is caused by four distinct, virus serotypes, which are transmitted to humans by Aedes aegypti mosquito. Dengue fever is epidemic in several countries of Asia-pacific and Latin America region. The growing global epidemic of dengue in aforementioned regions is expected to create demand for the dengue vaccine over the forecast period.
Increasing initiatives from local governments and World Health Organization (WHO) to curb the dengue menace across the regions expected to drive the market demand for dengue vaccine over the forecast period. Moreover, several governments are actively looking for incorporating dengue vaccine in routine immunization programmes to prevent the dengue epidemics. According to WHO estimates, there are around 50 Mn dengue infections worldwide every year and dengue is endemic in over 100 countries across the globe.
Asia-Pacific region expected to lead the global dengue vaccines market owing to widespread prevalence and incidence of dengue fever and large population, who are at dengue fever risk. Latin America expected to register highest market growth among all regions owing to the early adoption of the vaccine in government immunization programmes.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2025-2031 |
|
Market Size in 2024 |
US$ 661.9 million |
|
Market Size in 2031 |
US$ 1,445.0 million |
|
Market CAGR |
12.8% |
|
By Vaccine Type |
|
|
By End User |
|
|
By Region |
|
Download Free Sample Report
The dengue vaccine market size was valued at US$ 661.9 million in 2024 and is expected to reach US$ 1,445.0 million by 2031, growing at a significant CAGR of 11.8% from 2025-2031.
The market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
The market key players Takeda Pharmaceutical Company Limited, Serum Institute of India Pvt. Ltd, Panacea Biotec Limited, Sanofi Pasteur Limited, GeneOne Life Science, Sun Pharmaceutical Industries Ltd.
| 1. Executive Summary |
| 2. Global Dengue Vaccine Market Introduction |
| 2.1. Global Dengue Vaccine Market - Taxonomy |
| 2.2. Global Dengue Vaccine Market - Definitions |
| 2.2.1. Vaccine Type |
| 2.2.2. End User |
| 2.2.3. Region |
| 3. Global Dengue Vaccine Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Key Developments |
| 4. Global Dengue Vaccine Market By Vaccine Type, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 4.1. Live attenuated Vaccine |
| 4.1.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 4.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.1.3. Market Opportunity Analysis |
| 4.2. DNA Vaccine |
| 4.2.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 4.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.2.3. Market Opportunity Analysis |
| 4.3. Peptide Based Vaccine |
| 4.3.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 4.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.3.3. Market Opportunity Analysis |
| 4.4. Subunit based Vaccine |
| 4.4.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 4.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.4.3. Market Opportunity Analysis |
| 4.5. mRNA based Vaccine |
| 4.5.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 4.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 4.5.3. Market Opportunity Analysis |
| 5. Global Dengue Vaccine Market By End User, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 5.1. Hospitals and Clinics |
| 5 1 1 Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Government Institutes |
| 5.2.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Non-Governmental Organization (NGOs) |
| 5.3.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6. Global Dengue Vaccine Market By Region, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 6.1. North America |
| 6.1.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Europe |
| 6.2.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Asia Pacific |
| 6.3.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Latin America |
| 6.4.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. MEA |
| 6.5.1. Market Analysis, 2020-2024 and Forecast, 2025-2031, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Global Dengue Vaccine Market - Opportunity Analysis Index, By End User, Vaccine Type, and Region, 2025-2031 |
| 7. North America Dengue Vaccine Market, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 7.1. Vaccine Type Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 7.1.1. Live attenuated Vaccine |
| 7.1.2. DNA Vaccine |
| 7.1.3. Peptide Based Vaccine |
| 7.1.4. Subunit based Vaccine |
| 7.1.5. mRNA based Vaccine |
| 7.2. End User Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 7.2.1. Hospitals and Clinics |
| 7.2.2. Government Institutes |
| 7.2.3. Non-Governmental Organization (NGOs) |
| 7.3. Country Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 7.3.1. USA |
| 7.3.2. Canada |
| 8. Europe Dengue Vaccine Market, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 8.1. Vaccine Type Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1. Live attenuated Vaccine |
| 8.1.2. DNA Vaccine |
| 8.1.3. Peptide Based Vaccine |
| 8.1.4. Subunit based Vaccine |
| 8.1.5. mRNA based Vaccine |
| 8.2. End User Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1. Hospitals and Clinics |
| 8.2.2. Government Institutes |
| 8.2.3. Non-Governmental Organization (NGOs) |
| 8.3. Country Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1. Germany |
| 8.3.2. France |
| 8.3.3. Italy |
| 8.3.4. Spain |
| 8.3.5. UK |
| 8.3.6. Rest of Europe |
| 9. Asia Pacific Dengue Vaccine Market, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 9.1. Vaccine Type Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Live attenuated Vaccine |
| 9.1.2. DNA Vaccine |
| 9.1.3. Peptide Based Vaccine |
| 9.1.4. Subunit based Vaccine |
| 9.1.5. mRNA based Vaccine |
| 9.2. End User Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1. Hospitals and Clinics |
| 9.2.2. Government Institutes |
| 9.2.3. Non-Governmental Organization (NGOs) |
| 9.3. Country Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1. China |
| 9.3.2. Japan |
| 9.3.3. South Korea |
| 9.3.4. India |
| 9.3.5. Rest of APAC |
| 10. Latin America Dengue Vaccine Market, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 10.1. Vaccine Type Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Live attenuated Vaccine |
| 10.1.2. DNA Vaccine |
| 10.1.3. Peptide Based Vaccine |
| 10.1.4. Subunit based Vaccine |
| 10.1.5. mRNA based Vaccine |
| 10.2. End User Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Hospitals and Clinics |
| 10.2.2. Government Institutes |
| 10.2.3. Non-Governmental Organization (NGOs) |
| 10.3. Country Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1. Brazil |
| 10.3.2. Mexico |
| 10.3.3. Argentina |
| 10.3.4. Rest of Latin America |
| 11. MEA Dengue Vaccine Market, 2020-2024 and Forecast 2025-2031 (Sales Value USD Million) |
| 11.1. Vaccine Type Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Live attenuated Vaccine |
| 11.1.2. DNA Vaccine |
| 11.1.3. Peptide Based Vaccine |
| 11.1.4. Subunit based Vaccine |
| 11.1.5. mRNA based Vaccine |
| 11.2. End User Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Hospitals and Clinics |
| 11.2.2. Government Institutes |
| 11.2.3. Non-Governmental Organization (NGOs) |
| 11.3. Country Analysis, 2020-2024 and Forecast 2025-2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1. GCC Countries |
| 11.3.2. South Africa |
| 11.3.3. Rest of MEA |
| 12. Competition Landscape |
| 12.1. Strategic Dashboard of Top Market Players |
| 12.2. Company Profiles (Introduction, Financial Analysis, By Product Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 12.2.1. Sanofi |
| 12.2.2. Takeda |
| 12.2.3. Merck & Co |
| 12.2.4. Gylden Pharma |
| 12.2.5. Panacea Biotec |
| 12.2.6. Butantan Institute |
| 12.2.7. Indian Immunologicals Limited (IIL) |
| 12.2.8. Serum Institute of India |
| 12.2.9. GeneOne Life Science Inc. |
| 13. Research Methodology |
| 14. Key Assumptions and Acronyms |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.